How to buy Adamas Pharmaceuticals stock (ADMS)

Adamas Pharmaceuticals is a drug manufacturers - specialty & generic business based in the US. Adamas Pharmaceuticals shares (ADMS) are listed on the NASDAQ and all prices are listed in US Dollars. Adamas Pharmaceuticals employs 138 staff and has a trailing 12-month revenue of around $88.2 million.

Our top picks for where to buy Adamas Pharmaceuticals stock

Buy Adamas Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Adamas Pharmaceuticals stock price (NASDAQ: ADMS)

Use our graph to track the performance of ADMS stocks over time.

Adamas Pharmaceuticals shares at a glance

• Key figures

Information last updated 2022-01-23.

52-week range	$0.00 - $0.00
50-day moving average more info button	$7.00
200-day moving average more info button	$5.54
Wall St. target price	$8.52
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.62

Is it a good time to buy Adamas Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Adamas Pharmaceuticals financials

Revenue TTM	$88.2 million
Gross profit TTM	$72.4 million
Return on assets TTM	-15.4%
Return on equity TTM	0%
Profit margin	-71.11%
Book value	$0.13
Market Capitalization more info button	$376.4 million

TTM: trailing 12 months

Adamas Pharmaceuticals share dividends

We're not expecting Adamas Pharmaceuticals to pay a dividend over the next 12 months.

Adamas Pharmaceuticals share price volatility

Over the last 12 months, Adamas Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adamas Pharmaceuticals's is 2.8156. This would suggest that Adamas Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Adamas Pharmaceuticals overview

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc.

Frequently asked questions

null
What percentage of Adamas Pharmaceuticals is owned by insiders or institutions?
Currently 0.714% of Adamas Pharmaceuticals shares are held by insiders and 79.346% by institutions. How many people work for Adamas Pharmaceuticals?
Latest data suggests 138 work at Adamas Pharmaceuticals. When does the fiscal year end for Adamas Pharmaceuticals?
Adamas Pharmaceuticals's fiscal year ends in December. Where is Adamas Pharmaceuticals based?
Adamas Pharmaceuticals's address is: 1900 Powell Street, EmeryVille, CA, United States, 94608 What is Adamas Pharmaceuticals's ISIN number?
Adamas Pharmaceuticals's international securities identification number is: US00548A1060 What is Adamas Pharmaceuticals's CUSIP number?
Adamas Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 00548A106